Trial Profile
An open label, prospective, cohort study to evaluate the efficacy of switching from Efavirenz based regimen to Rilpivirine based regimen in HIV-1 infected patients with dyslipidemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Efavirenz
- Indications HIV-1 infections
- Focus Therapeutic Use
- 20 Dec 2015 New trial record